|1.||Okamoto, Masato: 18 articles (10/2015 - 11/2002)|
|2.||Sato, Mitsunobu: 13 articles (07/2013 - 11/2002)|
|3.||Tano, Tomoyuki: 11 articles (07/2013 - 11/2002)|
|4.||Oshikawa, Tetsuya: 10 articles (09/2006 - 11/2002)|
|5.||Ryoma, Yoshiki: 9 articles (08/2007 - 09/2002)|
|6.||Aoyagi, Masaru: 7 articles (02/2014 - 03/2003)|
|7.||Fukase, Shigeru: 7 articles (02/2014 - 03/2003)|
|8.||Ohta, Nobuo: 7 articles (02/2014 - 03/2003)|
|9.||Kan, Shin: 7 articles (07/2013 - 11/2004)|
|10.||Moriya, Yoichiro: 7 articles (01/2008 - 11/2002)|
11/01/1987 - "However, it was also observed that most of the R1-3B3- cells that killed MADB106 tumor cells were: 1) phenotypically or functionally different from either cytotoxic T-cells or typical NK cells; 2) observed only in MADB106 tumor-bearing rats challenged with OK-432; 3) not present on day 1-2 following OK-432 injection, the time when YAC-1 killing was maximally augmented; and 4) present in high numbers in a secondary response following reinoculation of the MADB106 tumor cells into cured rats. "
11/01/1992 - "The present study was designed to determine the optimal therapeutic protocol for OK-432, a streptococcal preparation, and to clarify the kinetics of various immunological parameters following intracutaneous administration of OK-432 in 39 disease-free postoperative patients with early cancer. "
09/01/1991 - "A randomized prospective study of 1011 gastrectomized cancer patients treated with oral OK432 showed significantly good results, especially in n(+) cases with curative resection. "
10/01/2005 - "Anti-tumor effect of OK-432 in TLR9-deficient mice was significantly but partially reduced as compared with that in wild-type mice, while the effect of OK-432 was almost completely eliminated in TLR4-deficient mice. "
12/15/1994 - "However, analysis based on stage showed that a preoperative intratumoral injection of OK-432 significantly improved the 5-year survival rate of patients with Stage III cancer (P = 0.0229), at 47.7% for the OK-432 group and 27.5% for the control group. "
|2.||Lymphangioma (Cavernous Lymphangioma)
03/01/1991 - "The results suggest that intralesional OK-432 therapy is effective for most unresectable lymphangiomas."
07/01/2009 - "Although OK-432 is predictably-effective against lymphangioma, it should not perform be applied without careful consideration."
03/01/2003 - "OK-432 injection was effective in approximately one third of children with lymphangioma. "
04/01/2000 - "OK-432 proved to be effective for primitive as well as for residual and recurrent lymphangioma. "
07/01/2007 - "The results of this study so far indicate that OK-432 is an effective and safe tool for the treatment of lymphangioma of head and neck region. "
|3.||Stomach Neoplasms (Stomach Cancer)
07/01/1994 - "Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion."
04/01/1987 - "A long term small-dose intratumoral administration of OK-432 seemed to be effective for a local recurrence of gastric cancer."
09/01/2002 - "Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials."
04/01/1988 - "The clinical efficacy of oral OK-432 on gastric cancer patients has been examined by a controlled randomized trial involving a total of about 1000 cases. "
01/14/2006 - "A meta-analysis of phase III trials with OK-432 suggested that immunochemotherapy may improve survival of patients with curatively resected gastric cancer. "
|4.||Neoplasm Metastasis (Metastasis)
10/01/1995 - "As a result, MLN metastasis was significantly suppressed and survival rate was significantly improved in every protocol as compared to mice without OK-432 administration. "
01/01/1993 - "In stage II without lymph node metastasis, 5-year disease free rate was significantly higher in the OK-432 group."
02/01/2001 - "This study showed that only one time preoperative OK-432 it, particularly when it triggers TILs, is effective for reduction of regional lymph node metastasis. "
10/01/1995 - "Administration of OK-432 prior to the surgical stress or ASGM 1 was at least partly effective for prevention of the hepatic metastasis and prolonged the survival of the inoculated mice. "
08/01/1993 - "The clinical course of this case suggests that OK-432 might have effectively treated lung metastases of HCC, although the exact mechanisms are at present unclear."
11/01/2010 - "Our results confirmed that OK-432 therapy is simple, easy, safe, and effective and can be used as a substitute for surgery in the treatment of benign neck cysts. "
11/01/2008 - "Intracystic injection of OK-432 may be a safe and effective treatment for benign thyroid cysts."
11/01/2008 - "Although OK-432 is a safe and effective sclerosing agent used to treat benign cystic lesions, little is known about its effectiveness in thyroid cysts. "
11/01/2010 - "The aim of this study was to evaluate the outcome and mechanism of action of OK-432 therapy in benign neck cysts. "
04/01/2007 - "Between March 2002 and March 2006, a prospective observational study was carried out to assess the effects of Picibanil on cervical cysts. "
|6.||Fibrinogen (Factor I)
|4.||Drug Therapy (Chemotherapy)